Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_1

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

NCT07164976
recruitingphase_3

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
recruitingphase_1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432

Clinical Trials (3)

Showing 3 of 3 trials
NCT07164976Phase 1

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Recruiting
NCT06377852Phase 3

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
NCT05216432Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3